Shanghai Fosun Pharmaceutical (SHA:600196) obtained registrations for two drugs from China's food and drug administrator, according to a Monday filing with the Shanghai bourse.

Polymyxin B sulfate for injection is intended for treating gram-negative bacterial infections resistant to conventional therapy, while labetalol hydrochloride injection is used to treat severe hypertension and for controlling hypotension during anesthesia.

Shares of the pharmaceutical company were down 1% in recent trade.